Instalco AB (4IIA) News

Optima Health PLC chief executive Jonathan Thomas talked with Proactive's Stephen Gunnion about the company's acquisition of Ireland-based Cognate Health. This deal marks Optima Health’s first foray outside the UK and is aligned with its strategy to supplement organic growth through mergers and acquisitions. Thomas said the move adds around €7 million in revenue and approximately £1 million in EBITDA to the group. Cognate Health is described as a strong platform with 30 clinic facilities across Ireland and around 60 experienced personnel, along with a network of clinicians. According to Thomas, “It’s a really great platform… in addition to obviously the financial aspects… really great opportunities to collaborate, revenue synergies and grow the businesses collectively.” He explained that expanding into a new regulated market provides access to multinational clients seeking services across both the UK and Ireland. The acquisition allows Optima Health to tailor services across jurisdictions while opening up new cross-sell opportunities. Thomas added that the company expects to announce more acquisitions during the year, with several discussions currently underway. Visit Proactive’s YouTube channel for more in-depth business updates and interviews. Don’t forget to give the video a like, subscribe to the channel, and enable notifications so you never miss a story. #OptimaHealth #CognateHealth #HealthcareAcquisition #MergersAndAcquisitions #JonathanThomas #OccupationalHealth #WorkplaceWellbeing #IrelandHealthcare #BusinessExpansion #ProactiveInvestors

Jeremy Salt, CEO of The Vaccine Group (TVG), a Frontier IP Group PLC portfolio company, talked with Proactive's Stephen Gunnion about the company’s collaboration with global animal health firm Syva. Salt explained that the partnership focuses on developing a vaccine for Streptococcus suis, a major disease in pigs that also contributes significantly to the use of antibiotics in livestock farming. “One of the key aspects of this collaboration with them is that they have a significant gap in their portfolio of products for pigs,” Salt noted. He emphasised that Streptococcus suis is prevalent in around 60% of European countries and impacts pig farming worldwide, with antimicrobial resistance (AMR) being a critical concern. The zoonotic nature of the disease, particularly in Southeast Asia, adds another layer of urgency to develop effective solutions. Salt highlighted that TVG’s vaccine platform provides broader protection across multiple strains, making it potentially globally applicable. The vaccine can be administered to young piglets, which is strategically important and is also expected to be more cost-effective than conventional options. He also discussed the role of UK government support, with Innovate UK and DEFRA grants contributing around £1 million in funding. The company is also progressing with 12 vaccine candidates, including developments in poultry and biotherapeutics delivery using monoclonal antibodies. For more updates, visit Proactive's YouTube channel. Don't forget to like the video, subscribe to the channel, and turn on notifications for future content. #AnimalHealth #Vaccines #SwineIndustry #AntimicrobialResistance #BiotechNews #TVG #FrontierIP #ProactiveInvestors #PigHealth #ZoonoticDiseases #LivestockFarming #VeterinaryInnovation #MonoclonalAntibodies #PoultryVaccines #Biotherapeutics

Caledonia Mining Corporation PLC chief executive Mark Learmonth talked with Proactive's Stephen Gunnion about a record first quarter for gold production at the company's Blanket Mine. Learmonth attributed the strong operational performance to significant management changes and the restructuring of the mine's operations, which split underground and surface responsibilities. “We've got a new, younger, more energetic management team underground... and it's worked beautifully,” Learmonth noted, highlighting the benefits of recent personnel shifts and structural reforms. The conversation also covered the recent $22.35 million sale of Caledonia’s solar power plant in Zimbabwe. While the asset has been sold, Learmonth said the company retains a long-term power supply agreement and the option to participate in a second phase, if viable. He clarified the decision allows Caledonia to concentrate more on its core gold mining business. Looking ahead, Learmonth said the company remains focused on maximising gold production while intensifying efforts to reduce long-term costs. “At this gold price, with production strong, we want to get that gold out the ground... with increasing attention now to more management focus on getting those costs down,” he said. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel and enable notifications for future content. #CaledoniaMining #GoldProduction #BlanketMine #ZimbabweMining #MarkLearmonth #MiningNews #SolarEnergy #EnergyResilience #GoldMining #ProactiveInvestors

European Green Transition PLC (AIM:EGT) founder and non-executive chairman Cathal Friel talked with Proactive's Stephen Gunnion about his formal move into the non-executive chairman role and the company’s strategy going forward. Friel shared how European Green Transition (EGT) aims to build value by acquiring distressed yet revenue-generating assets, a model he has successfully applied with previous companies such as Amryt Pharma and hVIVO. “Our model going forward is to acquire low-priced, distressed, good value assets, bolt them together,” he said, emphasising the need for revenue-generating components or the capacity to make acquisitions profitable from day one. He reflected on EGT’s IPO in April 2024 and his transition from other responsibilities, including his long tenure with hVIVO. With that chapter closed, he now brings more focus to EGT’s growth. Friel confirmed that the company still holds the majority of the £6.5 million raised, having only used a small portion on its rare earth asset in Sweden. Monetising that asset remains a priority. EGT's strategy continues to centre on small teams, tight cost control, and targeting multi-fold returns over a 24-month horizon. “I’ll be very careful of [the shareholders’] cash. It’s like mine,” Friel added. Visit Proactive’s YouTube channel for more interviews. Don’t forget to like this video, subscribe, and turn on notifications so you never miss an update. #CathalFriel #EuropeanGreenTransition #EGT #RareEarths #MergersAndAcquisitions #SmallCapInvesting #GreenEconomy #MiningInvestment #ShareholderValue #hVIVO #AmrytPharma #IPO